For instance, in a mouse model of melanoma that does not typically respond to immune checkpoint therapy, treatment with RAF, MEK, and FAK inhibitors alongside immune checkpoint inhibition significantly prolongs overall survival [74]. This evidence concerns the gene PTK2 and melanoma.